<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atorvastatin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atorvastatin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atorvastatin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8949" href="/d/html/8949.html" rel="external">see "Atorvastatin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11577" href="/d/html/11577.html" rel="external">see "Atorvastatin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F55989370"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Statin Pregnancy Contraindication Update</span>
<span class="collapsible-date">July 2021</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">After a comprehensive review of all available data, the FDA is requesting all statin manufacturers to remove the contraindication in the prescribing information against using statins in pregnant patients. Although statin therapy should be discontinued in most pregnant patients, health care providers should consider the ongoing therapeutic needs of the individual patient, especially patients at very high risk of cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolemia or those with established cardiovascular disease. Additionally, breastfeeding is still not recommended in patients taking a statin; health care providers should determine whether it is better to temporarily stop statin therapy while breastfeeding or to continue statin therapy and not have the patient breastfeed. If ongoing statin treatment is necessary, infant formula and other alternatives are available. The FDA expects that removing the contraindication will enable health care providers and patients to make individual decisions about benefit and risk, especially for those at very high risk of heart attack or stroke.</p>
<p style="text-indent:0em;">Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy&amp;token=gxfbJKP%2B4jbjRRe1dXCv59qhZFmTmV73qmf%2FX%2BpwMjvINmMExoP9r7EcTZq6LKtsQ%2FwwXarvQCVId0NgjG9XzdICKlsdFJ73s%2FDoyuycmVDaUZCyqN73GrYM2%2BxRAta2zcZQxGheSuTnwZzuZPE4Up8XPwPhb7srLeP9xEjjtcA%3D&amp;TOPIC_ID=12908" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137661"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Atorvaliq;</li>
<li>Lipitor</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866001"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Atorvastatin Calcium;</li>
<li>AG-Atorvastatin;</li>
<li>APO-Atorvastatin;</li>
<li>Atorvastatin-10;</li>
<li>Atorvastatin-20;</li>
<li>Atorvastatin-40;</li>
<li>Atorvastatin-80;</li>
<li>Auro-Atorvastatin;</li>
<li>BIO-Atorvastatin;</li>
<li>DOM-Atorvastatin [DSC];</li>
<li>JAMP-Atorvastatin;</li>
<li>JAMP-Atorvastatin Calcium;</li>
<li>Lipitor;</li>
<li>M-Atorvastatin;</li>
<li>Mar-Atorvastatin;</li>
<li>MINT-Atorvastatin;</li>
<li>MYLAN-Atorvastatin;</li>
<li>NRA-Atorvastatin;</li>
<li>PMS-Atorvastatin;</li>
<li>PMSC-Atorvastatin;</li>
<li>PRIVA-Atorvastatin [DSC];</li>
<li>PRZ-Atorvastatin;</li>
<li>REDDY-Atorvastatin;</li>
<li>RIVA-Atorvastatin;</li>
<li>SANDOZ Atorvastatin;</li>
<li>TARO-Atorvastatin;</li>
<li>TEVA-Atorvastatin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056610"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antilipemic Agent</span>;</li>
<li>
<span class="list-set-name">HMG-CoA Reductase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F137686"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f1668c0-6fbb-4528-a616-05cda10bb99a">Heterozygous familial and nonfamilial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial and nonfamilial hypercholesterolemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Begin treatment if after adequate trial (6 to 12 months) of intensive lifestyle modification emphasizing body weight normalization and diet, the following are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C ≥190 mg/dL or</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C remains ≥160 mg/dL and 2 or more cardiovascular risk factors: family history of premature atherosclerotic cardiovascular disease (&lt;55 years of age); overweight; obesity; or other elements of insulin resistance syndrome or</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C ≥130 mg/dL and diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18596007','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18596007','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;10 years of age (Tanner stage I): Limited data available: Oral: Initial: 5 mg once daily; if target LDL-C not achieved after 4 weeks, may increase incrementally by doubling dose (10 mg/day, 20 mg/day) at monthly intervals until target LDL-C; usual maximum daily dose: 40 mg/<b>day</b>; however, in some cases doses up to 80 mg/<b>day</b> have been used; dosing based on a long-term trial (3 years) of 272 patients (age range: 6 to 15 years); doses of 80 mg/day were used in 12 patients &lt;10 years of age; over the 3 year study duration, similar efficacy was observed without growth or maturation impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27678432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27678432'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 10 to 17 years: Oral: Initial: 10 mg once daily; if target LDL-C not achieved after 4 weeks, may increase incrementally by doubling dose (20 mg/day, 40 mg/day) at monthly intervals until target LDL-C up to a maximum daily dose: 80 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27678432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27678432'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="560908d5-ebc4-44c2-80e2-fb9e5eb5b6b8">Hyperlipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia:</b> Limited data available: Children and Adolescents 10 to 17 years (males and postmenarchal females): Oral: Initial: 10 mg once daily; if LDL-C target not achieved after 1 to 3 months, may increase to meet target LDL-C; in pediatric patients with heterozygous familial hypercholesterolemia, a maximum titrated dose based upon LDL response: 80 mg/<b>day</b> was used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27678432','lexi-content-ref-17377073','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27678432','lexi-content-ref-17377073','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b28cba34-da4d-4a8d-b5a0-b05d39419a87">Transplantation post-heart; prevention of cardiac allograft vasculopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transplantation post-heart; prevention of cardiac allograft vasculopathy (CAV):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate following heart transplantation regardless of baseline cholesterol levels in children and adolescents with high risk for rejection and CAV (eg, retransplantation, elevated panel reactive antibodies) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29492382','lexi-content-ref-20643330','lexi-content-ref-23714284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29492382','lexi-content-ref-20643330','lexi-content-ref-23714284'])">Ref</a></span>). Significant drug interactions between statins and immunosuppressant drugs are frequent; many interactions can increase statin serum concentrations and risk of toxicity (eg, myopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30485535','lexi-content-ref-27754879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30485535','lexi-content-ref-27754879'])">Ref</a></span>); consult drug interactions database for more detailed information.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 0.2 mg/kg/day rounded to nearest 2.5 mg increment; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12431495','lexi-content-ref-18466431','lexi-content-ref-20643330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12431495','lexi-content-ref-18466431','lexi-content-ref-20643330'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Muscle symptoms (potential myopathy): Children ≥10 years and Adolescents: Discontinue use until symptoms can be evaluated; check CPK level; based on experience in adult patients, also evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution (symptoms and any associated CPK abnormalities), resume the original or consider a lower dose of atorvastatin and retitrate. If muscle symptoms recur, discontinue atorvastatin use. After muscle symptom resolution, may reinitiate a different statin at an initial low dose; gradually increase if tolerated. Based on experience in adult patients, if muscle symptoms or elevated CPK persists for 2 months in the absence of continued statin use, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.1','lexi-content-ref-24222016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.1','lexi-content-ref-24222016'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51065113"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> Children ≥10 years and Adolescents: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> There are no recommendations in the manufacturer's labeling (has not been studied); however, atorvastatin is highly protein bound, making it unlikely to be cleared by dialysis. Based on adult experience, it is poorly dialyzed and no dosage adjustment or supplemental dose is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12686673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12686673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> There are no recommendations for dosing in patients undergoing peritoneal dialysis. Based on adult experience, it is poorly dialyzed and no dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15860377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15860377'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51065114"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.</p></div>
<div class="block doa drugH1Div" id="F137666"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8949" href="/d/html/8949.html" rel="external">see "Atorvastatin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Atorvastatin 40 to 80 mg/day is considered a high-intensity statin (generally reduces low-density lipoprotein cholesterol [LDL-C] by ≥50%). Atorvastatin 10 to 20 mg/day is considered a moderate-intensity statin (generally reduces LDL-C by ~30% to 49%). Assess response ~1 to 3 months after initiation of therapy or dose adjustment and every 3 to 12 months thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use in conjunction with lifestyle modification (eg, diet, exercise). When initiating therapy and selecting dose intensity, consider age, baseline LDL-C, 10-year atherosclerotic cardiovascular disease risk, risk-enhancing factors, potential adverse effects, and drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="355cd99a-0024-4930-8b95-6aee3ac5d71d">Heterozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hypercholesterolemia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2020.1','lexi-content-ref-11558482','lexi-content-ref-14636905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2020.1','lexi-content-ref-11558482','lexi-content-ref-14636905'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High-intensity therapy: Oral: Initial: 40 or 80 mg once daily; if 40 mg once daily is initiated and tolerated, increase to 80 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Multiple lipid-lowering therapies are usually needed to achieve treatment goals; treatment should be guided by an experienced lipid specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenson.2020.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenson.2020.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High-intensity therapy: Oral: 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenson.2020.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenson.2020.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4d76cb4-430b-418c-bf7b-688e7bf30bd0">Prevention of atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of atherosclerotic cardiovascular disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If LDL-C goal (eg, percent reduction or absolute goal) is not met with the initial dose, may consider up-titration based on estimated 10-year ASCVD risk (see ACC/AHA ASCVD Risk Estimator Plus online), LDL-C response, and tolerability. If LDL-C goal is not met with maximally tolerated dose, additional lipid-lowering therapy may be warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Primary prevention:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>without </i>diabetes, age 40 to 75 years, and LDL-C 70 to 189 mg/dL: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>ASCVD 10-year risk 5% to &lt;7.5%: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest shared decision-making if ASCVD 10-year risk is 5% to 10%; however, in patients with a baseline LDL-C &gt;160 mg/dL, statin therapy is usually recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>ASCVD 10-year risk </i>
<i>≥7.5% to &lt;20%: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest initiating moderate-intensity statin therapy in most patients if ASCVD 10-year risk is &gt;10% to &lt;20% and an LDL-C &gt;100 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49%; higher risk patients with multiple risk-enhancing factors may benefit from higher doses to reduce LDL-C by ≥50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>ASCVD 10-year risk </i>
<i>≥20%:</i> High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%; if unable to tolerate due to adverse effects, may reduce dose to maximum tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>with</i> diabetes:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Age 40 to 75 years <b>without</b> additional ASCVD risk factors: </i>Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>ASCVD risk ≥7.5% <b>or </b>multiple ASCVD risk factors:</i> High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%; if unable to tolerate due to adverse effects, may reduce dose to maximum tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-36031461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients with LDL-C ≥190 mg/dL and age 20 to 75 years: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> High-intensity therapy indicated regardless of ASCVD risk calculation or coexisting diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:8em;">High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%; if unable to tolerate due to adverse effects, may reduce dose to maximum tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Secondary prevention in patients with established atherosclerotic cardiovascular disease (eg, coronary heart disease, cerebrovascular disease [ischemic stroke or transient ischemic attack], peripheral arterial disease):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients with high-risk ASCVD may require additional therapies to achieve LDL-C goal (eg, &lt;70 mg/dL or &lt;50 mg/dL if very high risk).</p>
<p style="text-indent:-2em;margin-left:6em;">High-intensity therapy: Oral: 80 mg once daily to reduce LDL-C by ≥50%; if unable to tolerate due to adverse effects, may reduce dose to maximum tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-34024117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-34024117'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecca964d-8cd8-4a02-ba31-39237595cbed">Transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transplantation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Certain immunosuppressive drugs can induce or exacerbate hypercholesterolemia. Significant drug interactions between statins and immunosuppressant drugs are frequent; some interactions can increase statin serum concentrations and risk of toxicity (eg, myopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-20643330','lexi-content-ref-KDIGO.1','lexi-content-ref-Lentine.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-20643330','lexi-content-ref-KDIGO.1','lexi-content-ref-Lentine.2022'])">Ref</a></span>). Consult drug interactions database for more detailed information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transplantation, post heart (off-label use):</i> Oral:</b> Initial: 10 mg once daily starting 1 to 2 weeks after transplant, regardless of baseline cholesterol levels; increase dose based on response, tolerability, and use of concomitant medications up to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-20643330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-20643330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transplantation, post kidney (off-label use): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The decision to initiate therapy for primary or secondary prevention is similar to the non-transplant population (see the "<b>Prevention of atherosclerotic cardiovascular disease</b>" indication). However, in patients who are 30 to 39 years of age, some experts suggest statin therapy post-kidney transplantation for primary prevention of ASCVD. For primary prevention of ASCVD in patients 18 to 29 years of age, use shared decision making while considering risks and benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lentine.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lentine.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 10 mg once daily; increase dose based on response, tolerability, and use of concomitant medications up to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-Lentine.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-Lentine.2022'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed doses:</i> Oral suspension: If a dose is missed by &gt;12 hours, omit that dose and administer the next dose at the regularly scheduled time; do not administer extra doses to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991109"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9549635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9549635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12686673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12686673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15860377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15860377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988410"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team<i>: </i>Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although use is contraindicated in patients with active liver failure or decompensated cirrhosis according to the manufacturer's labeling, baseline elevation in AST/ALT should not preclude use of statins for compelling indications in patients with chronic stable liver disease including compensated cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139553','lexi-content-ref-15131789','lexi-content-ref-30423393','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139553','lexi-content-ref-15131789','lexi-content-ref-30423393','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Hepatic impairment prior to treatment initiation: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139553','lexi-content-ref-30660733','lexi-content-ref-29684459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139553','lexi-content-ref-30660733','lexi-content-ref-29684459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class B: Note: </b>Consider use only when benefit likely outweighs risk (eg, secondary prevention in patients with established atherosclerotic cardiovascular disease, including ischemic stroke, transient ischemic attack, peripheral artery disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: 20 mg once daily; maximum recommended dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33726685','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33726685','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class C: </b>Use of a hydrophilic statin (eg, rosuvastatin) is recommended. If use of atorvastatin is deemed necessary: Initial: 10 mg once daily; a maximum dose of 10 mg once daily is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Acute hepatotoxicity or worsening of hepatic function (eg, progression from Child-Turcotte-Pugh class A to B) during treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A:</b> Although use is contraindicated in patients with active liver failure or decompensated cirrhosis according to the manufacturer's labeling, if atorvastatin-induced hepatoxicity has been ruled out, may continue atorvastatin therapy with no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139553','lexi-content-ref-30660733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139553','lexi-content-ref-30660733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression to Child-Turcotte-Pugh class B and C:</b> Although use is contraindicated in patients with active liver failure or decompensated cirrhosis according to the manufacturer's labeling, if atorvastatin-induced toxicity (eg, liver injury, rhabdomyolysis) has been ruled out, may continue atorvastatin therapy with no dosage adjustment necessary; however, in patients with decompensated cirrhosis, consider not exceeding 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23889738','lexi-content-ref-29624871','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23889738','lexi-content-ref-29624871','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Continued use of statin therapy may be hepatoprotective in patients with decompensated cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28880449','lexi-content-ref-Singh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28880449','lexi-content-ref-Singh.1'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54861344"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Statins are associated with <b>increased serum transaminases</b> and hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>). Asymptomatic transient or persistent increases both &lt;3 or &gt;3 times the ULN in serum transaminases may occur with all statins; the increase in ALT is typically greater than the increase in AST (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>). Additionally, there are postmarketing reports of fatal and nonfatal <b>hepatic failure</b>, consisting of a cholestatic/mixed pattern (more common with atorvastatin) or hepatocellular pattern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21889469','lexi-content-ref-16777499','lexi-content-ref-14740794','lexi-content-ref-14642636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21889469','lexi-content-ref-16777499','lexi-content-ref-14740794','lexi-content-ref-14642636'])">Ref</a></span>). Drug-induced <b>autoimmune hepatitis</b> has also been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16940892','lexi-content-ref-15030994','lexi-content-ref-24700436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16940892','lexi-content-ref-15030994','lexi-content-ref-24700436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Upon dose reduction or discontinuation, transaminase levels return to or near pretreatment levels; although, mild elevations resolve with continued use in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581330','lexi-content-ref-24729773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581330','lexi-content-ref-24729773'])">Ref</a></span>). Chronic liver injury (defined as liver biochemical or histological abnormalities that persisted for 6 months or more after onset) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25075655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25075655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; inhibition of the CYP450 system, leading to increased plasma concentrations of statins has been postulated, as well as an immune-mediated response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17723922','lexi-content-ref-16777499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17723922','lexi-content-ref-16777499'])">Ref</a></span>). Changes in the lipid components of the hepatocyte membrane may lead to increased permeability and leakage of liver enzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20360293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20360293'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur within the first 3 months of initiation or dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15198967','lexi-content-ref-21889469','lexi-content-ref-16777499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15198967','lexi-content-ref-21889469','lexi-content-ref-16777499'])">Ref</a></span>). Duration of atorvastatin prior to development of hepatotoxicity has been reported from ∼1 month to 10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21889469','lexi-content-ref-24700436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21889469','lexi-content-ref-24700436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Administration of high oral daily dose of lipophilic drugs that undergo extensive hepatic metabolism, such as atorvastatin, may increase the risk of developing drug-induced liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25463547','lexi-content-ref-26983033']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25463547','lexi-content-ref-26983033'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications with statin drug-drug interactions or hepatotoxic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatotoxicity is more commonly associated with atorvastatin than pravastatin, rosuvastatin, and simvastatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21889469','lexi-content-ref-27860156','lexi-content-ref-26983033']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21889469','lexi-content-ref-27860156','lexi-content-ref-26983033'])">Ref</a></span>). Fluvastatin is associated with the greatest risk of developing hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21889469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21889469'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between different statins and the susceptibility to hepatotoxicity is unknown, as data have shown conflicting results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28979175','lexi-content-ref-21889469','lexi-content-ref-20360293','lexi-content-ref-19826975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28979175','lexi-content-ref-21889469','lexi-content-ref-20360293','lexi-content-ref-19826975'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic hepatitis B and alcohol consumption are independent risk factors for hepatic aminotransferase elevation associated with statins in patients 80 years of age or older (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31842780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31842780'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Muscle-related effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Statins are associated with several muscle-related effects, including:</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Myalgia</b> (muscle symptoms without significant creatine kinase [CK] elevations; also known as statin-associated muscle symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29473763','lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29473763','lexi-content-ref-25694464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Myopathy</b> (defined as unexplained muscle pain or weakness accompanied by a CK ≥10 times the ULN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Rhabdomyolysis</b> (CK &gt;40 times the ULN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>) often with acute renal failure secondary to myoglobinuria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29496886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29496886'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Immune-mediated necrotizing myopathy</b> (IMNM) (elevated CK plus the presence of antibodies against HMG-CoA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30430215','lexi-content-ref-31247184','lexi-content-ref-30944904','lexi-content-ref-31791994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30430215','lexi-content-ref-31247184','lexi-content-ref-30944904','lexi-content-ref-31791994'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Uncertain; alterations in the mevalonate pathway and changes in the electrical and structural characteristics of the sarcolemma related to calcium ion flux possibly contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18001622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18001622'])">Ref</a></span>). Decreased ubiquinone, which is essential for energy production in skeletal muscle, may also contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15210526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15210526'])">Ref</a></span>). Myopathy/rhabdomyolysis risk is related to circulating active drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581332'])">Ref</a></span>). IMNM is considered an immune-mediated process; autoantibodies against HMG-CoA reductase (anti-HMG-CoA) have been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791994'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; often presents within a few months after starting therapy (highest risk within first year of use), when the dose of the statin is increased, or when introducing an interacting drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575','lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575','lexi-content-ref-25694464'])">Ref</a></span>). Muscle symptoms often appear more promptly when patients are reexposed to the same statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25694464'])">Ref</a></span>). Duration of statin use prior to development of IMNM is ~2 to 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30430215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30430215'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• First year of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Addition of an interacting drug (eg, concurrent use of strong CYP3A4 inhibitors or medications associated with myopathy [eg, colchicine]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting muscle disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27484241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27484241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heavy exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher HMG-CoA reductase inhibitory activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30443347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30443347'])">Ref</a></span>), rosuvastatin &gt; atorvastatin &gt; simvastatin &gt; pravastatin ≈ lovastatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Although incidence increases with dose for most statins, there was no difference found in incidence with atorvastatin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16377285','lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16377285','lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian population: Increased plasma concentrations (up to ≈ twofold with atorvastatin) may result in increased risk of myopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F137632"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (7% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hemorrhagic stroke (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (6%), nausea (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Atorvastatin: Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,365</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,366</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (3% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Limb Pain table link" class="lexi-table-link" data-table-id="lexi-content-limb-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-limb-pain')">table 2</a>)</span><span class="table-link" style="display:none;">Limb Pain</span>, muscle spasm (2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Muscle Spasm table link" class="lexi-table-link" data-table-id="lexi-content-muscle-spasm" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-muscle-spasm')">table 3</a>)</span><span class="table-link" style="display:none;">Muscle Spasm</span>, musculoskeletal pain (2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Musculoskeletal Pain table link" class="lexi-table-link" data-table-id="lexi-content-musculoskeletal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-musculoskeletal-pain')">table 4</a>)</span><span class="table-link" style="display:none;">Musculoskeletal Pain</span>, myalgia (3% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Myalgia table link" class="lexi-table-link" data-table-id="lexi-content-myalgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-myalgia')">table 5</a>)</span><span class="table-link" style="display:none;">Myalgia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Limb Pain" frame="border" id="lexi-content-limb-pain" rules="all">
<caption style="text-align:center;">
<b>Atorvastatin: Adverse Reaction: Limb Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">604</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,908</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,055</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Muscle Spasm" frame="border" id="lexi-content-muscle-spasm" rules="all">
<caption style="text-align:center;">
<b>Atorvastatin: Adverse Reaction: Muscle Spasm</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,908</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">604</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,055</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Musculoskeletal Pain" frame="border" id="lexi-content-musculoskeletal-pain" rules="all">
<caption style="text-align:center;">
<b>Atorvastatin: Adverse Reaction: Musculoskeletal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">604</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,908</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,055</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Myalgia" frame="border" id="lexi-content-myalgia" rules="all">
<caption style="text-align:center;">
<b>Atorvastatin: Adverse Reaction: Myalgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atorvastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">604</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,908</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,055</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7,311</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngolaryngeal pain (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, eructation, flatulence</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling, muscle fatigue, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash, erythema multiforme, exacerbation of psoriasis (Cozzani 2009), lichenoid eruption (Forouzan 2020), Stevens-Johnson syndrome, toxic epidermal necrolysis (Pfeiffer 1998), urticaria (Adcock 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Merli 2010), pancreatitis (Lai 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (interstitial) (Huang 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Narayanan 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Russo 2014), hepatic failure, hepatitis (Saha 2021), increased gamma-glutamyl transferase (Xu 2020), increased serum alkaline phosphatase (Xu 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Hampson 2005), drug reaction with eosinophilia and systemic symptoms (Zereshkian 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Dermatomyositis (Spiro 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV (Wu 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (reversible; including amnesia, confusion, memory impairment) (Tuccori 2014), depression, dizziness, fatigue, myasthenia (Dobbels 2015), nightmares (Gregoor 2006), peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Immune-mediated necrotizing myopathy (Hasan 2020), increased creatine phosphokinase in blood specimen (Parker 2013), myopathy (Nemati 2021), myositis (including necrotizing autoimmune myositis) (Akivis 2022), rhabdomyolysis (Dalugama 2018), rupture of tendon (Marie 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (Abdelmasih 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Annigeri 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease</p></div>
<div class="block coi drugH1Div" id="F137646"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioneurotic edema, erythema multiforme, Steven Johnson syndrome, toxic epidermal necrolysis) to atorvastatin or any component of the formulation; acute liver failure or decompensated cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian</i>
<i> labeling:</i> Additional contraindications (not in US labeling): Concurrent therapy with boceprevir, cyclosporine, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ledipasvir/sofosbuvir, simeprevir, telaprevir, or velpatasvir/sofosbuvir.</p></div>
<div class="block war drugH1Div" id="F137629"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: May rarely worsen or precipitate myasthenia gravis (MG); monitor for worsening MG if treatment is initiated (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Stroke: Patients with recent stroke or TIA receiving long-term therapy with high-dose (ie, 80 mg/day) atorvastatin may be at increased risk for hemorrhagic stroke (SPARCL Investigators [Amarenco 2006]). A subsequent post-hoc analysis demonstrated that patients with lacunar or hemorrhagic stroke may be at higher risk of hemorrhagic stroke; however, this finding was determined to be hypothesis generating. The overall benefit of treatment with atorvastatin (ie, reduced risk of stroke and cardiovascular events) in this population seems to outweigh the increased risk of hemorrhagic stroke if one truly exists (Goldstein 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995).</p></div>
<div class="block foc drugH1Div" id="F137639"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as calcium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atorvaliq: 20 mg/5 mL (150 mL) [contains ethylparaben, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipitor: 10 mg, 20 mg, 40 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>
<div class="block geq drugH1Div" id="F137625"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F137648"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Atorvaliq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/5 mL (per mL): $1.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Atorvastatin Calcium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.02 - $7.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.03 - $10.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.04 - $10.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.06 - $10.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lipitor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $14.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $21.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $21.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $21.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866002"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipitor: 10 mg, 20 mg, 40 mg, 80 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>
<div class="block admp drugH1Div" id="F52612273"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to meals or time of day. The manufacturer's labeling states tablets should not be broken; however, available data do not indicate any safety or efficacy concerns with this practice.</p></div>
<div class="block adm drugH1Div" id="F137643"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Administer on an empty stomach, at least 1 hour before or 2 hours after a meal; may take without regard to time of day. Measure dose using a calibrated oral syringe or other oral dosing device containing scored metric units of measurement (eg, mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Administer with or without food; may take without regard to time of day. The manufacturer's labeling states tablets should not be broken; however, available data do not indicate any safety or efficacy concerns with this practice.</p></div>
<div class="block sts drugH1Div" id="F8002332"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Store in original container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Discard any unused portion within 60 days of opening the bottle.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565549"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Adjunct to dietary therapy in pediatric patients with heterozygous familial hypercholesterolemia if LDL-C remains ≥190 mg/dL, or if ≥160 mg/dL with family history of premature CHD or presence of ≥2 cardiovascular risk factors (FDA approved in ages 10 to 17 years); adjunct to dietary therapy to decrease elevated serum total and LDL-C, apolipoprotein B (apo-B), and triglyceride levels, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); adjunct treatment of homozygous familial hypercholesterolemia (FDA approved in adults); treatment of isolated hypertriglyceridemia (Fredrickson type IV); treatment of primary dysbetalipoproteinemia (Fredrickson Type III) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Primary prevention of cardiovascular disease in high risk patients (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used in prevention of cardiac allograft vasculopathy.</p></div>
<div class="block mst drugH1Div" id="F137707"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Atorvastatin may be confused with atomoxetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin</p>
<p style="text-indent:2em;">HMG-CoA reductase inhibitors (when referred to as "statins") may be confused with nystatin.</p>
<p style="text-indent:-2em;margin-left:4em;">Lipitor may be confused with labetalol, Levatol, lisinopril, Loniten, Lopid, Mevacor, Zocor, ZyrTEC</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F137693"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F137634"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Atorvastatin. Management: Use of atorvastatin and atazanavir/cobicistat is not recommended. Use the lowest atorvastatin dose necessary and titrate carefully in patients taking atazanavir or atazanavir/ritonavir due to the increased risk of myopathy, including rhabdomyolysis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Avoid use of bezafibrate and HMG-CoA reductase inhibitors (statins) unless strictly indicated due to the increased of muscle toxicity (including rhabdomyolysis). In patients who may be predisposed to myopathy, concomitant use is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May enhance the adverse/toxic effect of Atorvastatin. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Atorvastatin. Management: Limit atorvastatin to a maximum dose of 20 mg/day when used with clarithromycin.  If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Atorvastatin. Management: Avoid the combined use of atorvastatin with atazanavir/cobicistat. Atorvastatin dose should not exceed 20 mg daily when combined with other cobicistat-containing regimens.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping statin (HMG-CoA reductase inhibitor) therapy prior to daptomycin. If daptomycin is used with a statin, creatine phosphokinase (CPK) monitoring could be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May increase the serum concentration of Atorvastatin. Management: Use the lowest atorvastatin dose necessary and limit the atorvastatin dose to 20 mg daily in patients taking darunavir. Monitor patients for signs and symptoms of myopathy at initiation of therapy and with any dose increase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Atorvastatin may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: May increase the serum concentration of Atorvastatin. Management: Limit the adult dose of atorvastatin to a maximum of 20 mg/day when used together with elbasvir and grazoprevir. Use the lowest atorvastatin dose necessary and monitor closely for evidence of statin-related toxicities such as myalgia or myopathy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of Atorvastatin. Encorafenib may decrease the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Atorvastatin may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may increase the serum concentration of Atorvastatin.  Management: Use the lowest atorvastatin dose necessary and limit the atorvastatin dose to 20 mg daily in patients taking fosamprenavir. Monitor patients for signs and symptoms of myopathy at initiation of therapy and with any dose increase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest possible starting statin dose and monitor patients closely for statin-related adverse effects (eg, muscle aches and pains) during coadministration with fostemsavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Atorvastatin. Management: Avoid large quantities of grapefruit juice (more than 1.2 liters daily) during treatment with atorvastatin. Monitor for atorvastatin adverse effects (eg, myopathy, rhabdomyolysis) in patients who consume smaller quantities or whose intake has changed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: May increase the serum concentration of Atorvastatin. Management: Use the lowest atorvastatin dose necessary and titrate carefully in patients taking indinavir. Monitor patients carefully for signs and symptoms of myopathy and rhabdomyolysis during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Atorvastatin. Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Atorvastatin may enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Administer HMG-CoA reductase inhibitors (eg, statins) at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: May enhance the adverse/toxic effect of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of Atorvastatin. Management: Limit the atorvastatin dose to 20 mg daily when combined with letermovir. When letermovir is coadministered with cyclosporine, the use of atorvastatin (at any dose) is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: May increase the serum concentration of Atorvastatin. Atorvastatin may increase the serum concentration of Lomitapide. Management: When the lomitapide dose is 10 mg daily or greater, reduce the lomitapide dose by 50% when combined with atorvastatin. No dose adjustment is required when the lomitapide dose is 5 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May increase the serum concentration of Atorvastatin. Management: Consider the risks and benefits of this combination. If coadministered, use the lowest dose of atorvastatin necessary and monitor patients for signs and symptoms of myopathy, especially at initiation of therapy and with any dose increase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: Atorvastatin may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May increase the serum concentration of Atorvastatin. Management: Use the lowest atorvastatin dose necessary in patients taking nelfinavir, and do not exceed atorvastatin 40 mg daily. Monitor patients for signs and symptoms of myopathy at initiation of therapy and with any dose increase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Atorvastatin. Management: Consider temporarily discontinuing atorvastatin during treatment with nirmatrelvir/ritonavir. It is not necessary to hold atorvastatin either prior to or after completion of nirmatrelvir/ritonavir treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oteseconazole: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May increase the serum concentration of Atorvastatin. RifAMPin may decrease the serum concentration of Atorvastatin. Management: Administer atorvastatin and rifampin simultaneously if using both. Monitor atorvastatin response closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Atorvastatin. Management: Use lowest atorvastatin dose needed. If ritonavir is combined with another protease inhibitor, see the drug interaction monograph for that protease inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). Management: Monitor patients receiving rolapitant for increased exposure to and/or effects of BCRP/ABCG2 substrates.  Use the lowest effective rosuvastatin dose when used in combination with rolapitant.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacubitril: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May increase the serum concentration of Atorvastatin. Management: Limit the atorvastatin dose to 20 mg in patients taking saquinavir and ritonavir. Monitor patients for signs and symptoms of myopathy at initiation of therapy and with any dose increase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Atorvastatin. Management: The maximum atorvastatin dose should not exceed 40 mg/day with concurrent use of simeprevir, and use of the lowest necessary atorvastatin dose is recommended. Monitor for atorvastatin toxicity with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease serum concentrations of the active metabolite(s) of HMG-CoA Reductase Inhibitors (Statins). Management: Consider avoiding the concomitant administration of St John's Wort with atorvastatin, lovastatin and simvastatin in order to avoid the potential for decreased effects statins.  If coadministered, monitor for decreased statin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafamidis: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Atorvastatin may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Atorvastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: May increase the serum concentration of Atorvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: Atorvastatin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of Atorvastatin.  Management: Consider using lower doses of atorvastatin when used together with verapamil, and monitor closely for signs of HMG-CoA reductase inhibitor toxicity (eg, myositis, rhabdomyolysis, hepatotoxicity).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of Atorvastatin. Management: Use the lowest atorvastatin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities (eg, myopathy, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F137658"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Atorvastatin serum concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities of grapefruit juice (&gt;1.2 liters/day).</p></div>
<div class="block dic drugH1Div" id="F137649"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 3 to 6 months and the diet should be continued during drug therapy. Atorvastatin serum concentration may be increased when taken with grapefruit juice; avoid concurrent intake of large quantities (&gt;1.2 liters/day).</p>
<p style="text-indent:-2em;margin-left:2em;">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003).</p></div>
<div class="block rep_considerations drugH1Div" id="F49095568"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Adequate contraception is recommended if an HMG-CoA reductase inhibitor (statin) is required in patients who may become pregnant (AHA/ACC [Grundy 2019a]; CCS [Pearson 2021]). Patients planning to become pregnant should discuss their lifetime risk of cardiovascular disease, as well as risks and benefits of statin therapy with their health care team (CCS [Pearson 2021]). When appropriate, statins can be discontinued 1 to 2 months prior to conception (AHA/ACC [Grundy 2019a]).</p>
<p style="text-indent:0em;margin-top:2em;">When a statin is needed in a patient of reproductive potential, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred to limit placental transfer (CCS [Pearson 2021]).</p></div>
<div class="block pri drugH1Div" id="F1757842"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In healthy pregnancies, changes in lipid synthesis occur that are required for normal placental and fetal growth. Low-density lipoprotein cholesterol and triglycerides increase as pregnancy progresses and decline postpartum. HMG-CoA reductase inhibitors (statins) decrease the synthesis of cholesterol and substances derived from cholesterol. Therefore, based on the mechanism of action, in utero exposure may cause fetal harm (Lecarpentier 2012); however, data from available studies have not shown an increased risk of major congenital anomalies following first trimester exposure (Bateman 2015; Chang 2021; Vahedian-Azimi 2021a). Additional data are needed to evaluate other pregnancy outcomes, such as miscarriage (Vahedian-Azimi 2021b).</p>
<p style="text-indent:0em;margin-top:2em;">Because there is potential for fetal harm, statins should be discontinued once pregnancy is recognized (AHA/ACC [Grundy 2019a]; Brunham 2018). If lipid-lowering therapy during pregnancy is required, it should be individualized based on the therapeutic needs of the patient, considering the lifetime risk of untreated disease, use of nonstatin therapies, as well as the known risks and benefits of statins. Based on limited data, when a statin is needed in a pregnant patient, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred. Lipophilic statins (eg, atorvastatin, fluvastatin, lovastatin, simvastatin, pitavastatin) may be more likely to cross the placenta and increase the risk of congenital malformations (AHA/ACC [Grundy 2019a]; CCS [Pearson 2021]; Lecarpentier 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Additional data are needed to clarify the role of statins for the prevention of atherosclerotic cardiovascular disease in at-risk pregnant patients (AHA/ACC [Grundy 2019a]; CCS [Pearson 2021]; Parikh 2021).</p></div>
<div class="block mopp drugH1Div" id="F53565550"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer's labeling: Consider neuromuscular and serologic testing if immune-mediated necrotizing myopathy is suspected​.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients: Baseline: ALT, AST, and CPK; fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT, and AST every 3 to 4 months during the first year and then every 6 months thereafter (NHLBI 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults:</p>
<p style="text-indent:-4em;margin-left:6em;">
<i>2013 ACC/AHA Blood Cholesterol Guideline recommendations</i> (Stone 2014):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>
<p style="text-indent:-2em;margin-left:6em;">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>
<p style="text-indent:-2em;margin-left:6em;">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer recommendation:</i> Liver enzyme tests at baseline and repeated when clinically indicated. Measure CPK when myopathy is being considered or may measure CPK periodically in high risk patients (eg, drug-drug interaction). Upon initiation or titration, lipid panel should be analyzed within 2 to 4 weeks.</p></div>
<div class="block pha drugH1Div" id="F137628"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>
<div class="block phk drugH1Div" id="F137645"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Initial changes: 3 to 5 days; Maximal reduction in plasma cholesterol and triglycerides: 2 to 4 weeks; LDL reduction: 10 mg/day: 39% (for each doubling of this dose, LDL is lowered approximately 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapidly absorbed; extensive first-pass metabolism in GI mucosa and liver</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~381 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥98%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4; forms active ortho- and parahydroxylated derivatives and an inactive beta-oxidation product; plasma concentrations are elevated in patients with chronic alcoholic liver disease and Child-Pugh class A and B liver disease</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~14% (parent drug); ~30% (parent drug and equipotent metabolites)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: ~14 hours; Equipotent metabolites: 20 to 30 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Bile (following hepatic and/or extra-hepatic metabolism; does not appear to undergo enterohepatic recirculation); urine (&lt;2% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51220454"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> and AUC are each 4-fold greater in patients with Child-Pugh class A disease; C<sub>max</sub> and AUC are ~16-fold and 11-fold increased, respectively, in patients with Child-Pugh class B disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma concentrations are higher (~40% for C<sub>max</sub> and 30% for AUC).</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Plasma concentrations in women differ from those in men (~20% higher for C<sub>max</sub> and 10% lower for AUC)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F137650"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Astatin | Ator | Atoris | Atorlip | Atortab | Atorva | Atstat | Aztor | Lipicure | Lipigard | Lipitor | Lipodar | Lipomax | Statix | Storvas | Torvacard | Torvacol | Tovast | Tulip | Vastor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Atarva | Ateroclar | Atorvamar | Atorvastan | Atorvastatina | Atorvastatina Cevallos | Atorvastatina Fabra | Faboxim | Finlipol | Kospidel | Liparex | Lipibec | Lipifen | Lipitor | Lipodren | Lipofin | Lipokemia | Liponorm | Lipovastatinklonal | Micinamar | Nexostatin | Normalip | Normolipol | Plan | Ronator | Sincol | Tecoplax | Vanator | Vast</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atorvalan | Atorvastatin | Atorvastatin 1a pharma | Atorvastatin accord | Atorvastatin Actavis | Atorvastatin aristo | Atorvastatin bluefish | Atorvastatin bluefish AB | Atorvastatin Easypharm | Atorvastatin G.L. | Atorvastatin Genericon | Atorvastatin HCS | Atorvastatin krka | Atorvastatin pfizer | Atorvastatin Pluspharma | Atorvastatin ranbaxy | Atorvastatin Ratiopharm | Atorvastatin stada | Atorvastatin viatris | Avatarstad | Betastatin | Sortis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Atorvachol | Atorvastatin | Atorvastatin Actavis | Atorvastatin an | Atorvastatin gh | Atorvastatin rbx | Atorvastatin scp | Lipitor | Lorstat | Noumed atorvastatin | Pharmacor atorvastatin | Stada atorvastatin | Terry white chemists atorvastatin | Torvastat | Trovas</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anzitor | Aster | Astin | Atasin | Atova | Atovex | Atovin | Atrovast | Atv | Avas | Avator | Avocard | Colostat | Divastin | Frenvas | Lipex | Lipicon | Lipicut | Lipiles | Lipistat | Lipitin | Lipiva | Liplo | Lipostat | Liptor | Livas | Locol | Onvas | Optivas | Orva | Orvatin | Os | Sb ator | Stacor | Taven | Tcl-R | Tigilo | Tiginor | Vass | Vastin | Xelitor | Xelpid | Xerova | Zapitor</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atorasat | Atorstatineg | Atorvastacalc | Atorvastatin ab | Atorvastatin apotex | Atorvastatin bepb | Atorvastatin krka | Atorvastatine eg | Atorvastatine Mylan | Atorvastatine Pfizer | Atorvastatine sandoz | Atorvastatine Teva | Lipitor | Tavara | Totalip</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Atorlip | Cholestrom | Lesstrol | Lipikind | Lipovas | Storvas | Tahor | Trova | Vastator | Vastor | X'tor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amicor | Aragil | Atorgamma | Atorgen | Atoris | Atorva | Atorvastatin AL | Atorvastatin aurobindo | Atorvastatin billev | Atorvastatin ecopharm | Atorvastatin Genericon | Atorvin | Atorvistat | Atorvistat k | Avanor | Calipra | Larus | Sortis | Torvacard | Torvalipin | Tulip</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Atorless | Atorvastatina | Atorvastatina calcica | Atorvastatina calcica geolab | Atorvasterol | Corastorva | Kolevas | Lipigran | Lipistat | Lipitor | Lipthal | Lumirarte | Vast | Volunta | Zarator</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atorva pfizer | Atorvastatin Actavis | Atorvastatin axapharm | Atorvastatin Helvepharm | Atorvastatin Mepha | Atorvastatin Mepha Teva | Atorvastatin pfizer | Atorvastatin Sandoz | Atorvastatin spirig | Atorvastatin spirig hc | Atorvastatin streuli | Atorvastatin zentiva | Atorvastax | Sortis</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Atorex | Atorfit | Atorlip | Atorvastatine | Atotin | Atroclass | Atron | Avas | Avastatin | Avstat | Carlipo | Lesstrol | Lipias | Lipiduce | Lipovas | Lolip | Optilip | Statinor | Tahor | Tora | Torva | Trova | Vaskol | Vastator | X'tor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Atenfar | Atorlip | Dislipor | Hipolixan | Lipitor | Lipoten | Lipotropic | Lipox | Lowden | Zarator</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A le | Lipitor | Mei da xin | You li ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Atorcol | Atorfit | Atorlip | Atorsyn | Atorvastatina | Atorvat | Atovarol | Axo | Cardiostatina | Controlip | Corastatin | Ectasil | Edy | Estatlen | Farmalip | Garmisch nivecol | Glustar | Hipolipin | Isulor | Lipicare | Lipitor | Lipostan | Lowlipen | Nivecol | Nivelar | Ormar | Pakadel | Riscol | Sin ater | Tabtina | Tarvastin | Torvastin | Vast</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amedo | Apo atorvastatin | Atorgamma | Atoris | Atorstad | Atorvastatin +Pharma | Atorvastatin 1a pharma | Atorvastatin Actavis | Atorvastatin aurovitas | Atorvastatin Egis | Atorvastatin Hbf | Atorvastatin medreg | Atorvastatin mylan | Atorvastatin Ratiopharm | Atorvastatin xantis | Atraven | Bisatum | Corat | Larus | Lipfix | Pharmtina | Sortis | Spatizalex | Torvacard | Torvacard neo | Torvazin | Triglyx | Tulip</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atorbem | Atorgamma | Atoris | Atorva Q | Atorvastatin | Atorvastatin 1 a pharma | Atorvastatin Aaa | Atorvastatin abz | Atorvastatin accord | Atorvastatin Actavis | Atorvastatin AL | Atorvastatin aristo | Atorvastatin aurobindo | Atorvastatin axiromed | Atorvastatin Basics | Atorvastatin Biomo | Atorvastatin CT | Atorvastatin Dexcel | Atorvastatin Hennig | Atorvastatin Heumann | Atorvastatin Hexal | Atorvastatin mylan | Atorvastatin puren | Atorvastatin Ratiopharm | Atorvastatin stada | Atorvastatin vivanta | Atorvastatin zentiva | Lipitor | Sortis</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Arvas | Atorvastatina | Atorvastin | Atrolip | Bioppal | Fravastatin | Hipovastin | Hopenor | Lesator | Lipatrol | Lipitor | Lipotrop | Orator | Redugrel | Rotaqor | Statin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ampliar | Atocor | Atorcross | Atorisk | Atorlip | Atorvastatina | Atorvastatina mk | Atrolip | Atvas | Lipitor | Liponorm | Lipotropic | Lipox | Lowden | Storvas | Triglicol | Vast</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atilen | Atorgamma | Atoris | Atorvastatin | Atorvastatin accord | Atorvastatin billev | Atorvastatin Medochemie | Atorvastatin Polpharma | Atorvastatin Portfarma | Atorvastatin Ratiopharm | Atorvastatin tad | Atorvastatin teva | Atorvastatin zentiva | Lopamol | Sortis | Torvacard | Tulip</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ator | Atorstat | Atovast | Borgastatin | Fatestatin | Lipicole | Lipiless | Lipinorm | Lipitor | Lipomax | Lipona | Lipovast | Orgovastin | Rostatine | Sigmalip | Torastatin | Torvast | Vonteroid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atoris | Atorvastatina Abex | Atorvastatina actavis group | Atorvastatina Almus | Atorvastatina alter | Atorvastatina alter farmacia | Atorvastatina amneal | Atorvastatina Apotex | Atorvastatina aristo | Atorvastatina aurobindo | Atorvastatina Bexal | Atorvastatina bluefish | Atorvastatina Cinfa | Atorvastatina Combix | Atorvastatina Davur | Atorvastatina Edigen | Atorvastatina Kern Pharma | Atorvastatina Korhispana | Atorvastatina krka | Atorvastatina Mabo | Atorvastatina mundogen | Atorvastatina mylan | Atorvastatina Mylan Pharmaceuticals | Atorvastatina Normon | Atorvastatina normon | Atorvastatina Pensa | Atorvastatina pharma combix | Atorvastatina Pharmacia | Atorvastatina Qualigen | Atorvastatina Ranbaxy | Atorvastatina ranbaxygen | Atorvastatina ratiopharm | Atorvastatina sandoz | Atorvastatina Stada | Atorvastatina stadagen | Atorvastatina Tarbis | Atorvastatina tecnigen | Atorvastatina Tevagen | Atorvastatina Urquima | Atorvastatina vir | Atorvastatina vivanta | Atorvastatina zentiva | Cardyl | Prevencor | Thervan | Zarator</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Atorin | Atorva | Atorvastatin | Atorvastatina Mabo | Atstat | Caditor | Cholvast | Lipiduce | Lipigard | Lipinorm | Lipor | Liptor | Mactor | Thervan | Vastor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atorbir | Atorvaratio | Atorvastatin accord | Atorvastatin actavis | Atorvastatin bluefish | Atorvastatin krka | Atorvastatin Leiras | Atorvastatin orion | Atorvastatin pfizer | Atorvastatin Ratiopharm | Atorvastatin Sandoz | Lipistad | Lipitor | Lipitor orifarm | Orbeos</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatine | Atorvastatine accord | Atorvastatine Actavis | Atorvastatine Almus | Atorvastatine Arrow | Atorvastatine Biogaran | Atorvastatine Bluefish | Atorvastatine Cristers | Atorvastatine eg | Atorvastatine Evolupharm | Atorvastatine isomed | Atorvastatine Krka | Atorvastatine Mylan | Atorvastatine Pfizer | Atorvastatine Phr | Atorvastatine RPG | Atorvastatine sandoz | Atorvastatine Teva | Tahor</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatin | Atorvastatin Almus | Lipitor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Altoram | Antorcin | Arvastatil | Ator chol | Atorcard | Atorgon | Atoridor | Atorlip | Atormax | Atorplus | Atorsild | Atorstat | Atorval | Atorvalet | Atorvanox | Atorvastatin/generics | Atorvastatin/krka | Atorvastatin/mylan | Atorvastatin/sandoz | Atorvastatin/tad | Atorvin | Atorzem | Atrost | Atrosterol | Atrovita | Biger | Card ok | Cardiostyl | Danelip | Delipost | Doss Medichrom | Fluxol M T F | Holisten | Latrovin | Lipigan | Lipimed | Lipitor | Lipium Raldex | Lipizem | Lipodial | Lipogen | Lipostatin | Lipovast | Lorvaten | Mexitory | Minolip | Nelibat | Provicard | Rafitin | Rotacor | Rotova | Tevastatin | Torvacard | Torvacard neo | Torvachol | Torvaplus | Torvastin | Vastazor | Xanator | Xolister all | Zarastin | Zarator</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Colvasten | Dislip</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Atacor | Atoris | Atorlip | Atorvastatin | Atorvastatin teva | Biotor 10 | Divator | Emstat | Lesstrol | Lipiduce | Lipiget | Lipistad | Lipitor | Lipivas | Lipiwon | Orvakline | Vaspitor | Vick Lipidstatin | Xtor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Artas | Atoris | Atorvastatin Genera | Atorvastatin PharmaS | Atorvox | Calipra | Liptin | MEDiStatin | Sortis | Synordia | Torvas | Tulip</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atorgamma | Atoris | Atorva teva | Atorvastatin 1a pharma | Atorvastatin krka | Atorvastatin Polpharma | Atorvastatin Q Pharma | Atorvastatin ranbaxy | Atorvastatin Ratiopharm | Atorvastatin teva | Atorvep | Copator | Decholest | Gletor | Hypolip | Liprimar | Obradon | Pharmastatin | Sortis | Torvalipin | Torvatec | Voredanin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actalipid | Atofar | Atorsan | Atorvastatin | Atorwin | Atostin | Cholestor | Covetor | Fastor | Lipidef | Lipitor | Litorcom | Livator | Nulipid | Orvast | Removchol | Stator | Stavinor | Tavora | Truvaz</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatin | Atorvastatin Clonmel | Atorvastatin krka | Atorvastatin mylan | Atorvastatin rowa | Lipitor | Torvacol | Torvan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lipitor | Litorva | Torid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A-vin | Ab vas | Acrostatin | Alistor | Alten | Altrip | Alvastatin | Alvotin | Aostin | Arpitor | Asat | Astin | Atalo | Atast | Atcasia | Atchol | Atevas | Atheart | Atix | Ato | Atocare | Atocer | Atocor | Atodin | Atofast | Atorbest | Atorcia | Atorcyn | Atorday | Atordil | Atordin | Atorec | Atorem | Atorfirst | Atorfit | Atorget | Atorica | Atoril | Atorin | Atorise | Atoritic | Atorkem | Atorlip | Atormac | Atormat | Atormed | Atornam | Atornet | Atoroll | Atorsave | Atorslim | Atortin | Atortus | Atorva | Atorvastatin | Atosar | Atosta | Atostat | Atr | Atrocard | Atrolar | Atrolet | Atrostat | Atstat | Attic | Attor | Atv | Atvas | Atvast | Atvastin | Atvel | Avas | Avastin | Avistatin | Avor | Azerva | Aztor | Barostatin | Biotor | Biovas | Caat | Caditor | Cardiozen | Cardistat | Cholechek | Cholestat | Cipvas | Cotrilo | Ctor | Dipolip | Dispitor | Durastat | Dyslip | Dysliptin | Esternex | Etovas | Eze | Genxvast | Hartor | Hypolin | Ibitor | Instatin | Itor | Latin | Ldlow | Ldtor | Lesskaa | Lesstrol | Lilo | Lipichek | Lipicor | Lipicure | Lipid | Lipigold | Lipikind | Lipiles | Lipinorm | Lipipres | Lipira | Lipiric | Lipisafe | Lipitab | Lipivas | Lipofix | Liponorm | Liporest | Lipvas | Lower A | Mactor | Modlip | Molvast | Monotorva | Morstat | Normator | Oltrova | Omnitor | Orvas | Orvastin | Ozovas | Pileca | Pleotor | Pritorva | Pulmistat | Qest | Redustat | Rotacor | Saanvas | Sitestat | Soraton | Statchol | Statfit | Statiga | Statix | Statlip | Stator | Stator-ez | Statwa | Storvas | Strovent | Tg tor | Tonact | Tor hdl | Torsa | Torvason | Trava | Turbostat | Tvs | Unitor | Vagator | Vagolip | Vasc | Vasolip | Vast | Vasta | Vedator | Vestan | Violip | Wolip | Xtor | Zivast</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Atorvasam | Atorvastatin | Atrovastatin awa | Kivas | Liponeer</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arkas | Atoris | Atorvastatina | Atorvastatina abc | Atorvastatina accord | Atorvastatina actavis | Atorvastatina Almus | Atorvastatina angenerico | Atorvastatina doc generici | Atorvastatina EG | Atorvastatina firma | Atorvastatina Germed | Atorvastatina git | Atorvastatina krka | Atorvastatina mylan | Atorvastatina nisura | Atorvastatina Pensa | Atorvastatina Ranbaxy | Atorvastatina sandoz | Atorvastatina tecnigen | Atorvastatina zentiva | Coleama | Lipitor | Melemib | Omegastatin | Sopavi | Taxat | Torastin | Torvacol | Torvast | Totalip | Tovanira | Vastat | Xarator</span>;</li>
<li>
<span class="countryCode">(JM)</span> <span class="country">Jamaica</span><span class="countrySeparator">: </span><span class="drugName">Lipirest</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aditor | Atorvast | Lipitor | Lipodar | Lipomax | Toralac | Tovast | Vastor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatin | Atorvastatin me | Lipitor</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arvaz | Astoril | Atocor | Atorcip | Atorec | Atorem | Atorfit | Atorid | Atorin | Atorlip | Atormed | Atorva | Atova | Atrona | Atstat | Avas | Avastatin | Aztor | Caditor | Cholestrom | Colastin L | Colestop | Dipitor | Lesstrol | Lipicon | Lipidrop | Lipiget | Lipikind | Lipilab | Lipimol | Lipitas | Lipitin a | Lipitor | Lipizar | Lipofix | Lipor | Lipsava | Locol | Lolip | Lowchol | Optilip | Storvas | Tg tor | Toralac | Torvast | Umestatin | Vastor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A Pito | A Stin | A tova | Actovar | Ador | Adwin | Aitatin | Alipid | Allfit | Alphastartin | Alphastatin | Altorva | Apecor | Apito | Aripid | Arito | Arostin | Arotatin | Arotin | Aroto | Arovan | Artech | Artin | Arva | Arvatin | Astan | Astatin | Atatin | Atocel s | Atolow | Atolva | Ator | Atoran | Atoren | Atorin | Atorix | Atorotin | Atorsan | Atorstan | Atorva | Atorvadid | Atorvan | Atorvastatin | Atorvastatin huons | Atorvatin | Atorvin | Atosan | Atosen | Atospo | Atostan | Atostar | Atostin | Atotatin | Atoterol | Atotin m | Atovan | Atovas | Atozal | Atrode | Atrovan | Aukovasta | Ava q | Avasta | Avatin | Barostatin | Bi pito | Bipito | Boriato | Cirmitor | Daewoongbio atorvastatin | Daviato | Eltorva | Farotin | Glosta | Hator | Huniz atorvastatin calcium | Hustar | Hutecs Atorvastatin | I rito | Il yang atorvastatin | Ilyangbio atorvastatin calcium trihydrate | Inist atorvastatin | K torva | Latova | Ldilow | Lipar | Lipiator | Lipiclean | Lipicure | Lipido | Lipien | Lipikhan | Lipilor | Lipilou | Lipino | Lipinon | Lipisante | Lipistatin | Lipistop | Lipitan | Lipiterol | Lipitol | Lipitop | Lipitor | Lipitrol | Lipiwon | Lipoactin | Lipomet | Litoatin | Livatin | Livato | Neustatin a | New atorta | Newpex | Newsta | Newtor | Newvast | Olpit | Pharmbio korea atorvastatin calcium hydrate | Radova | Resterol | Retostin | Retova | Ripia | Ripinon | Ripistin | Rivantin | Rivatadin | Rp vastatin | Ryvantin | Sandoz atorvastatin | Sofia | Speetin | Torvis | Tovast | Tovastin | Udamva | Unipito | Vastatin | Vator | Yungjin atorvastatin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atorlip | Lipigard | Lipiless | Lipitor | Lipomax | Lorvast | Toralac | Tovast</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Astatin | Ator | Atorec | Atorlip | Atorva | Atorvast | Atorvastatin | Atorvastatine arrow generiques | Emitor | Lipigard | Lipitor | Lipodar | Lipomax | Lorvast | Orbalip | Orvasta | Tarden | Toralac | Torstat | Torvacard | Torvalip | Tovast | Zyrotor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abaran | Astator | Atorgamma | Atoris | Atorvastatin Actavis | Atorvastatin billev | Atorvastatin Polpharma | Atorvastatin Portfarma | Atorvastatin Ratiopharm | Atorvastatin teva | Atorvastatin zentiva | Lopamol | Sortis | Torvacard | Torvarin | Tulip</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atorasat | Atorstatineg | Atorvastatin apotex | Atorvastatin Ratiopharm | Atorvastatine eurogenerics | Atorvastatine sandoz | Lipitor | Totalip</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amicor | Astator | Atilen | Atilen Actavis | Atorgamma | Atoris | Atorvastatin accord | Atorvastatin Actavis | Atorvastatin billev | Atorvastatin Polpharma | Atorvastatin Portfarma | Atorvastatin ranbaxy | Atorvastatin Ratiopharm | Atorvastatin tad | Atorvastatin teva | Lopamol | Sortis | Torvacard | Torvazin | Tulip</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Costal | Ld nor | Liptorva | Tahor | Torva</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apolistina | Atorlip | Atorvastatin | Atorvastatina | Atromcor | Bacat | Blodivit | Collipor | Deslocron | Dylaxyl | Eturion | Inastor | Inmetcol | Lipitor | Odivitor | Teinemia | Thoreva | Vascol | Xiadani</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Astatin | Atacor | Atoris | Atorvas | Atorvastatin | Crystorvas | Lipiduce | Lipistad | Lipitor | Orvakline | Rotaqor | Storvas | Synerrv atorvastatin | Trovem | Tulip</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Artom | Atocard | Atorec | Atorkem | Atorvastatin | Atostor | Atswift | Chovastin | Cidovastin | Filstatin | Grevast | Intracell's atorvastatin | Lipiduce | Lipitor | Medley atorvastatin | Shinfield atorvastatin | Sivovas | Solvastin | Storvas | Suvast | Torvastin | Tostin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atorab | Atorvastatin | Atorvastatin ranbaxy | Atorvastatine | Atorvastatine accord | Atorvastatine ratiopharm | Atorvastatine xiromed | Cardyl | Lipitor | Prevencor | Zarator</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatin | Atorvastatin accord | Atorvastatin aristo | Atorvastatin Hexal | Atorvastatin krka | Atorvastatin mylan | Atorvastatin pensa | Atorvastatin Pfizr | Atorvastatin Ratiopharm | Atorvastatin Sandoz | Atorvastatin teva | Atorvastatin xiromed | Lipitor | Sortis</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atorvastatin | Lipitor | Lorstat | Noumed atorvastatin | Zarator</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Torvast</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alkast | Ator | Atorquilab | Atorslim | Atorvast | Atorvastatina | Atovarol | Aztor | Biostatina | Corastatin | Lipimid | Lipitas | Lipitor | Lipotropic | Lipovastin | Storvas | Unovas</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Adivast | Atonamis | Ator | Ator 10 | Atorbet | Atorcad | Atorcal | Atormax | Atorphil | Atorsaph | Atorschwartz | Atorvacor | Atorvas | Atorvast natrapharm | Atorvastatin | Atorvastatin ritemed | Atorvastatin Sandoz | Atorwin | Atovas | Atv | Atvas | Avamax | Avas | Avator | Bestatin | Betorvas | Brelvastin | Cholduce | Cholesta | Choltrol | Dystatin | Florvast | Fulvast | Globastat | Itorvaz | Leztrol | Lipend | Lipiblac | Lipigo | Lipikhan | Lipiric | Lipitor | Lipivent | Lipotrim | Lofat | Lolip | Mayor | Metorvast | Mytorvas | Onestatin | Orvakline | Pharex Atorvastatin | Protorvas | Q tor | Ranvast | Redulip | Saatin | Stalip | Synator | Truvast | Vastor | Vazi2r | Xantor | Xentor | Zanvator | Zydusatorva</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Apetor | Astat | Atastan | Atavast | Atopitar | Atorax | Atorin | Atorlip | Atorlite | Atorpharm | Atorsan | Atorscot | Atorsim | Atorva | Atorviz | Atovas | Atrachol | Atrata | Atrocal | Atrow | Atvast | Caliptrol | Cholestor | Colezaf | Colstat | Delip | Descol | Etortin | Fatilor | Genovax | Hitor | Lastolip | Lipidin | Lipidip | Lipifal | Lipiget | Lipilow | Lipirex | Lipistat | Lipitor | Lipivas | Lipivastin | Lipotrim | Lochol | Lovas | Megavastin | Momentium | Myopro | Oravast | Orva | Orvast | Oscar | Pro-statin | Raytor | Reduse | Renorm | Ridlip | Rostinox | Save | Sensicon | Sotis | Stat A | Statin | Stator | Tavas | Tavist | Trovas | Truva | Univastin | Vasclear | Vasta | Vastor | Winstor | Zepitor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo atorva | Atorgamma | Atoris | Atorvagen | Atorvastatin Arrow | Atorvastatin bluefish | Atorvastatin genoptim | Atorvastatin ranbaxy | Atorvastatin teva | Atorvastatin Vitama | Atorvastatinum Farmacom | Atractin | Atrox | Corator | Ivistatyna | Lambrinex | Olvastim | Pharmastatin | Sortis | Storvas | Torvacard | Tulip | Voredanin | Xavitor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atorvaliq | Atorvastatin | Lipitor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atorvas | Atorvastatina | Atorvastatina actavis | Atorvastatina alter | Atorvastatina alter genericos | Atorvastatina atorvan | Atorvastatina aurobindo | Atorvastatina Azevedos | Atorvastatina bluepharma | Atorvastatina ciclum | Atorvastatina Cinfa | Atorvastatina daquimed | Atorvastatina Farmogene | Atorvastatina Farmoz | Atorvastatina Generis | Atorvastatina Germed | Atorvastatina gp | Atorvastatina krka | Atorvastatina labesfal | Atorvastatina mepha | Atorvastatina mylan | Atorvastatina pfizer | Atorvastatina pharmakern | Atorvastatina Ranbaxy | Atorvastatina ratiopharm | Atorvastatina sandoz | Atorvastatina tad | Atorvastatina tavitan | Atorvastatina tetrafarma | Atorvastatina teva | Atorvastatina tolife | Atorvastatina triangor | Atorvastatina wynn | Atorvastatina zentiva | Divastina | Zarator</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Atorlip | Atorvastatina | Atorvastatina caplin point | Atorvastatina cipla | Atorvastatina dallas | Atorvastatina medicine | Atorvastatina pasteur | Atorvastatina prosalud | Atorvastatina sandoz | Atorvastol | Hopenor | Liparex | Lipitor | Lipomax | Lipomin | Lipotropic | Torva | Vast</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aprolip | Astatin | Atorcor | Atorlip | Atstat | Cholvast | Colastin-L | Lipigard | Lipitor | Lipodar | Lipomax | Lorvast | Storvas | Torvacol | Torvastin | Tovast | Vastor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amicor | Ascord | Atilen | Atorgamma | Atoris | Atorvastatin ranbaxy | Atorvastatina accord | Atorvastatina aurobindo | Atorvastatina mylan | Atorvastatina teva | Atorvastatina torrent | Gletor | Sortis | Tulip | Xamara</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Anvistat | Atomax | Ator | Atoris | Atorvastatin | Atorvastatin alkaloid | Atorvastatin avexima | Atorvastatin k | Atorvastatin leksvm | Atorvastatin ms | Atorvastatin nanolek | Atorvastatin Obl | Atorvastatin tabuk | Atorvastatin teva | Atorvox | Lipoford | Lipona | Liprimar | Liptonorm | Torvas | Torvazin | Tulip | Vasator</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Astatin | Atorlip | Atorva | Ld nor | Lipicure | Lipitor | Lipodar | Tovast | Tulip</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atorab | Atorbir | Atorstad | Atorvastad | Atorvastatin 1a farma | Atorvastatin accord | Atorvastatin Actavis | Atorvastatin aristo | Atorvastatin bluefish | Atorvastatin ebb | Atorvastatin krka | Atorvastatin mylan | Atorvastatin orifarm | Atorvastatin orion | Atorvastatin pfizer | Atorvastatin ranbaxy | Atorvastatin Sandoz | Atorvastatin teva | Atorvastatin xirom | Lipistad | Lipitor | Tavara</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo atorvastatin | Atavor | Atocor | Atoris | Atorvon | Eturion | Lipitor | Torvalipin | Tulip</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atoris | Atorvastatin Actavis | Atorvastatin Lek | Atorvastatin stada | Atorvastatin zentiva | Bisatum | Lipitor | Sortis | Stavra | Torvacard | Torvalipin | Tulip</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amicor | Astator | Atorgamma | Atoridor | Atoris | Atorvastatin | Atorvastatin +Pharma | Atorvastatin Farmax | Atorvastatin Hbf | Atorvastatin Hikma | Atorvastatin mylan | Atorvastatin Polpharma | Atorvastatin stada | Atorvastatin teva | Atorvastatin xantis | Gletor | Pharmastatin | Sortis | Spatizalex | Torvacard | Torvacard novum | Torvazin | Tulip</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Atorsan | Atorvastatin Sandoz | Atorvin | Chlovas | Lipitor | Xarator</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ator | Atorvex | Atrovast | Cholestyl | Laptor | Statinor | Tahor | Tavastor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alvastin | As Atoks | Ateroz | Ator | Avitorel | Cholvast | Colastin L | Divator | Kolestor | Lipidra | Lipitaksin | Lipitor | Lipsum | Saphire | Tarden | Torvaxal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anxolightor | Anxolipo | Atorcal | Atorin | Atoroty | Atorva | Atotin | Atoty | Atova | Atover | Lightor | Lipikon | Lipiminus | Lipistad | Lipitor | Torvacard | Tulip</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Actastatin | Amvastan | Atorem | Atorem 40 | Atoris | Atormac | Atorvacor | Atorvastatin | Atorvastatin teva | Atorvasterol | Atotex | Atsat | Aztor | Emstat | Etset | Limistin | Lipitin | Lipitin a | Lipodemin | Liprimar | Livostor | Torvacard | Torvadac | Vasocleen</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Atorem | Atorfit | Atorin | Atorlip | Atorva | Atvin | Avas | Caditor | Colestop | Divator | Lipicure | Lipiduce | Lipitor | Lipizar | Lipodar | Lipor | Torvast | Vast</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Atorva | Atorvestol | Atosclerol | Hipovacor | Integrator | Lipitor | Liponorm | Normolip | Tovaris</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antip | Atorvastatina | Atorvid | Atovarol | Aztor | Colastin L | Estatlen | Filstatin | Glustar | Lipitor | Tarimyl | Teinemia | Volunta</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aforsatin | Amtopid | Apamtor | Aszolzoly | Ator vpc | Atorhasan | Atorpa | Atroact | Avasboston | Avastor | Bitorvas | Dorotor | Glovitor | Hacortin | Inbacid | Insuact | Lipidtab | Lipotatin | Lipvar | Normelip | Statinagi | Tormeg 10 | Troytor | Vasitor | Vaslor | Zoamco | Zyatin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Alipto | Aspavor | Astor | Atolip | Atorvastatin | Atorvastatin lhc | Atorvastatin unicorn | Atorvastatin winthrop | Dezzolip 10 | Dynator | Lestavor | Lipitor | Lipogen | Vasmak | Vastor</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aspavor | Atorec | Atorem | Atorfit | Atorin | Atorlip | Atorvastatin | Avastatin | Caditor | Lesstrol | Lipitas | Lipitor | Lolip | Modlip | Storvas | Tg tor | Tonact | Torvast</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Aspavor | Storvas</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34159019">
<a name="34159019"></a>Abdelmasih R, Abdelmaseih R, Reed J. A rare case of statin-induced diplopia: an often-overlooked but reported side effect. <i>Cureus</i>. 2021;13(5):e15117. doi:10.7759/cureus.15117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34159019/pubmed" id="34159019" target="_blank">34159019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11314923">
<a name="11314923"></a>Adcock BB, Hornsby LB, Jenkins K. Dermographism: an adverse effect of atorvastatin. <i>J Am Board Fam Pract</i>. 2001;14(2):148-151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/11314923/pubmed" id="11314923" target="_blank">11314923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30443347">
<a name="30443347"></a>Akimoto H, Negishi A, Oshima S, et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. <i>Pharmacol Res Perspect</i>. 2018;6(6):e00439. doi:10.1002/prp2.439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30443347/pubmed" id="30443347" target="_blank">30443347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36407864">
<a name="36407864"></a>Akivis Y, Kurup M, John S. Statin-induced necrotizing autoimmune myositis. <i>J Med Cases</i>. 2022;13(10):513-516. doi:10.14740/jmc4010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/36407864/pubmed" id="36407864" target="_blank">36407864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16940892">
<a name="16940892"></a>Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. <i>J Clin Gastroenterol</i>. 2006;40(8):757-761. doi:10.1097/00004836-200609000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16940892/pubmed" id="16940892" target="_blank">16940892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16899775">
<a name="16899775"></a>Amarenco P, Bogousslavsky J, Callahan A 3rd, et al, “High-Dose Atorvastatin After Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators,” <i>N Engl J Med</i>, 2006, 355(6):549-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16899775/pubmed" id="16899775" target="_blank">16899775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25684874">
<a name="25684874"></a>Annigeri RA, Mani RM. Acute interstitial nephritis due to statin and its class effect. <i>Indian J Nephrol</i>. 2015;25(1):54-56. doi:10.4103/0971-4065.136883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25684874/pubmed" id="25684874" target="_blank">25684874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atorvaliq.1">
<a name="Atorvaliq.1"></a>Atorvaliq (atorvastatin) [prescribing information]. Farmville, NC: CMP Pharma Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28880449">
<a name="28880449"></a>Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. <i>Aliment Pharmacol Ther</i>. 2017;46(7):673-680. doi:10.1111/apt.14243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/28880449/pubmed" id="28880449" target="_blank">28880449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25784688">
<a name="25784688"></a>Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. <i>BMJ</i>. 2015;350:h1035. doi:10.1136/bmj.h1035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25784688/pubmed" id="25784688" target="_blank">25784688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16581330">
<a name="16581330"></a>Bays H. Statin safety: an overview and assessment of the data--2005. <i>Am J Cardiol</i>. 2006;97(8A):6C-26C. doi:10.1016/j.amjcard.2005.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16581330/pubmed" id="16581330" target="_blank">16581330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17272627">
<a name="17272627"></a>Belay B, Belamarich PF, and Tom-Revzon C, "The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions," <i>Pediatrics</i>, 2007, 119(2):370-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/17272627/pubmed" id="17272627" target="_blank">17272627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15198967">
<a name="15198967"></a>Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. <i>Circulation</i>. 2004;109(23 Suppl 1):III50-III57. doi:10.1161/01.CIR.0000131519.15067.1f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15198967/pubmed" id="15198967" target="_blank">15198967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28979175">
<a name="28979175"></a>Bergland Ellingsen S, Nordmo E, Lappegård KT. Recurrence and severe worsening of hepatotoxicity after reintroduction of atorvastatin in combination with ezetimibe. <i>Clin Med Insights Case Rep</i>. 2017;10:1179547617731375. doi:10.1177/1179547617731375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/28979175/pubmed" id="28979175" target="_blank">28979175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al, “Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,” <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17723922">
<a name="17723922"></a>Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. <i>Clin Liver Dis</i>. 2007;11(3):597-vii. doi:10.1016/j.cld.2007.06.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/17723922/pubmed" id="17723922" target="_blank">17723922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21889469">
<a name="21889469"></a>Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. <i>J Hepatol</i>. 2012;56(2):374-380. doi:10.1016/j.jhep.2011.07.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/21889469/pubmed" id="21889469" target="_blank">21889469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27860156">
<a name="27860156"></a>Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. <i>Liver Int</i>. 2017;37(2):173-178. doi:10.1111/liv.13308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/27860156/pubmed" id="27860156" target="_blank">27860156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32139553">
<a name="32139553"></a>Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. <i>Gut</i>. 2020;69(5):953-962. doi:10.1136/gutjnl-2019-318237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/32139553/pubmed" id="32139553" target="_blank">32139553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30527143">
<a name="30527143"></a>Brunham LR, Ruel I, Aljenedil S, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. <i>Can J Cardiol</i>. 2018;34(12):1553-1563. doi:10.1016/j.cjca.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30527143/pubmed" id="30527143" target="_blank">30527143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20360293">
<a name="20360293"></a>Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. <i>Mayo Clin Proc</i>. 2010;85(4):349-356. doi:10.4065/mcp.2009.0365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/20360293/pubmed" id="20360293" target="_blank">20360293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDA.1">
<a name="CDA.1"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada," <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25463547">
<a name="25463547"></a>Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?. <i>J Hepatol</i>. 2015;62(3):751-752. doi:10.1016/j.jhep.2014.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25463547/pubmed" id="25463547" target="_blank">25463547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15131789">
<a name="15131789"></a>Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. <i>Gastroenterology</i>. 2004;126(5):1287-1292. doi:10.1053/j.gastro.2004.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15131789/pubmed" id="15131789" target="_blank">15131789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34967881">
<a name="34967881"></a>Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin exposure during pregnancy. <i>JAMA Netw Open</i>. 2021;4(12):e2141321. doi:10.1001/jamanetworkopen.2021.41321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34967881/pubmed" id="34967881" target="_blank">34967881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431495">
<a name="12431495"></a>Chin C, Gamberg P, Miller J, et al, "Efficacy and Safety of Atorvastatin After Pediatric Heart Transplantation," <i>J Heart Lung Transplant</i>, 2002, 21(11):1213-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12431495/pubmed" id="12431495" target="_blank">12431495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18466431">
<a name="18466431"></a>Chin C, Lukito SS, Shek J, et al, "Prevention of Pediatric Graft Coronary Artery Disease: Atorvastatin," <i>Pediatr Transplant</i>, 2008, 12(4):442-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18466431/pubmed" id="18466431" target="_blank">18466431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26983033">
<a name="26983033"></a>Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. <i>PLoS One</i>. 2016;11(3):e0151587. doi:10.1371/journal.pone.0151587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/26983033/pubmed" id="26983033" target="_blank">26983033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16777499">
<a name="16777499"></a>Clarke AT, Mills PR. Atorvastatin associated liver disease. <i>Dig Liver Dis</i>. 2006;38(10):772-777. doi:10.1016/j.dld.2006.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16777499/pubmed" id="16777499" target="_blank">16777499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi: 10.1016/j.healun.2010.05.034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21886735">
<a name="21886735"></a>Cozzani E, Scaparro M, Parodi A. A case of psoriasis worsened by atorvastatin. <i>J Dermatol Case Rep</i>. 2009;3(4):60-61. doi:10.3315/jdcr.2009.1037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/21886735/pubmed" id="21886735" target="_blank">21886735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29784023">
<a name="29784023"></a>Dalugama C, Pathirage M, Kularatne SAM. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. <i>J Med Case Rep</i>. 2018;12(1):143. doi:10.1186/s13256-018-1685-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29784023/pubmed" id="29784023" target="_blank">29784023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596007">
<a name="18596007"></a>Daniels SR, Greer FR, and Committee on Nutrition, "Lipid Screening and Cardiovascular Health in Childhood," <i>Pediatrics</i>, 2008, 122(1):198-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18596007/pubmed" id="18596007" target="_blank">18596007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12398573">
<a name="12398573"></a>de Denus S and Spinler SA, “Early Statin Therapy for Acute Coronary Syndromes,” <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12398573/pubmed" id="12398573" target="_blank">12398573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29492382">
<a name="29492382"></a>Dipchand AI. Current state of pediatric cardiac transplantation. <i>Ann Cardiothorac Surg</i>. 2018;7(1):31-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29492382/pubmed" id="29492382" target="_blank">29492382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26319449">
<a name="26319449"></a>Dobbels L, Van Damme P, Mahler M, Bossuyt X. A 62-year-old woman with muscle weakness. <i>Clin Chem</i>. 2015;61(9):1133-1135. doi:10.1373/clinchem.2014.227819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/26319449/pubmed" id="26319449" target="_blank">26319449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30430215">
<a name="30430215"></a>Essers D, Schäublin M, Kullak-Ublick GA, Weiler S. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. <i>Eur J Clin Pharmacol</i>. 2019;75(3):409-416. doi:10.1007/s00228-018-2589-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30430215/pubmed" id="30430215" target="_blank">30430215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368702">
<a name="11368702"></a>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). <i>JAMA</i>. 2001;285(19):2486-2497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/11368702/pubmed" id="11368702" target="_blank">11368702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32257699">
<a name="32257699"></a>Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced lichenoid drug eruption: a case report and review of statin-associated cutaneous adverse events. <i>Cureus</i>. 2020;12(3):e7155. doi:10.7759/cureus.7155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/32257699/pubmed" id="32257699" target="_blank">32257699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14740794">
<a name="14740794"></a>Gershovich OE, Lyman AE Jr. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. <i>Pharmacotherapy</i>. 2004;24(1):150-154. doi:10.1592/phco.24.1.150.34803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/14740794/pubmed" id="14740794" target="_blank">14740794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18077795">
<a name="18077795"></a>Goldstein LB, Amarenco P, Szarck M, et al, “Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study,” <i>Neurology</i>, 2008, 70(24 Pt 2):2364-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18077795/pubmed" id="18077795" target="_blank">18077795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26746989">
<a name="26746989"></a>Greenway SC, Butts R, Naftel DC, et al. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents. <i>J Heart Lung Transplant</i>. 2016;35(4):457-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/26746989/pubmed" id="26746989" target="_blank">26746989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16627511">
<a name="16627511"></a>Gregoor PJ. Atorvastatin may cause nightmares. <i>BMJ</i>. 2006;332(7547):950. doi:10.1136/bmj.332.7547.950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16627511/pubmed" id="16627511" target="_blank">16627511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019a;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30423393">
<a name="30423393"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.<i> J Am Coll Cardiol.</i> 2019b;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30423393/pubmed" id="30423393" target="_blank">30423393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31842780">
<a name="31842780"></a>Guo M, Zhao J, Zhai Y, Zang P, Lv Q, Shang D. A prospective study of hepatic safety of statins used in very elderly patients. <i>BMC Geriatr</i>. 2019;19(1):352. doi:10.1186/s12877-019-1361-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/31842780/pubmed" id="31842780" target="_blank">31842780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16228623">
<a name="16228623"></a>Hampson JP, Smith D, Cowell R, Baker A. Hypotension and eosinophilia with atorvastatin. <i>Pharm World Sci</i>. 2005;27(4):279-280. doi:10.1007/s11096-005-7115-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16228623/pubmed" id="16228623" target="_blank">16228623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628837">
<a name="20628837"></a>Harper CR, Jacobson TA. Evidence-based management of statin myopathy. <i>Curr Atheroscler Rep</i>. 2010;12(5):322-330. doi:10.1007/s11883-010-0120-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/20628837/pubmed" id="20628837" target="_blank">20628837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31247184">
<a name="31247184"></a>Hasan S, Abushahin A, Prayson R, Kilani A. When statins cause an autoimmune response: a report of a severe case of rhabdomyolysis. <i>Am J Med</i>. 2020;133(1):50-51. doi:10.1016/j.amjmed.2019.05.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/31247184/pubmed" id="31247184" target="_blank">31247184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30485535">
<a name="30485535"></a>Heeney SA, Tjugum SL, Corkish ME, Hollis IB. Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. <i>Clin Transplant</i>. 2019;33(1):e13454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30485535/pubmed" id="30485535" target="_blank">30485535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642. doi: 10.1161/CIR.0b013e31823b5fee.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29496886">
<a name="29496886"></a>Hilton-Jones D. Statin-related myopathies. <i>Pract Neurol</i>. 2018;18(2):97-105. doi:10.1136/practneurol-2017-00173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29496886/pubmed" id="29496886" target="_blank">29496886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22936996">
<a name="22936996"></a>Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. <i>PLoS One</i>. 2012;7(8):e42866. doi:10.1371/journal.pone.0042866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22936996/pubmed" id="22936996" target="_blank">22936996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28551957">
<a name="28551957"></a>Holmsen ST, Bakkebø T, Seferowicz M, Retterstøl K. Statins and breastfeeding in familial hypercholesterolaemia. <i>Tidsskr Nor Laegeforen</i>. 2017;137(10):686-687. doi:10.4045/tidsskr.16.0838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/28551957/pubmed" id="28551957" target="_blank">28551957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26184102">
<a name="26184102"></a>Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/26184102/pubmed" id="26184102" target="_blank">26184102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911072">
<a name="25911072"></a>Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25911072/pubmed" id="25911072" target="_blank">25911072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660733">
<a name="30660733"></a>Kaplan DE, Serper MA, Mehta R, et al; VOCAL Study Group. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. <i>Gastroenterology</i>. 2019;156(6):1693-1706.e12. doi:10.1053/j.gastro.2019.01.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30660733/pubmed" id="30660733" target="_blank">30660733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for lipid management in chronic kidney disease. <i>Kidney Int Suppl. </i>2013;3(3):259-305. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2013-Lipids-Guideline-English.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34024117">
<a name="34024117"></a>Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34024117/pubmed" id="34024117" target="_blank">34024117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23714284">
<a name="23714284"></a>Kobayashi D, Du W, L'ecuyer TJ. Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients. <i>Pediatr Transplant</i>. 2013;17(5):436-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23714284/pubmed" id="23714284" target="_blank">23714284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25679302">
<a name="25679302"></a>Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25679302/pubmed" id="25679302" target="_blank">25679302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886597">
<a name="26886597"></a>Lai SW, Lin CL, Liao KF. Atorvastatin use associated with acute pancreatitis: a case-control study in Taiwan. <i>Medicine (Baltimore)</i>. 2016;95(7):e2545. doi:10.1097/MD.0000000000002545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/26886597/pubmed" id="26886597" target="_blank">26886597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678432">
<a name="27678432"></a>Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. <i>J Clin Lipidol</i>. 2016;10(5):1153-1162.e3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/27678432/pubmed" id="27678432" target="_blank">27678432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637891">
<a name="18637891"></a>Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18637891/pubmed" id="18637891" target="_blank">18637891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15755765">
<a name="15755765"></a>LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>N Engl J Med</i>. 2005;352(14):1425-1435. doi:10.1056/NEJMoa050461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15755765/pubmed" id="15755765" target="_blank">15755765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15860377">
<a name="15860377"></a>Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. <i>Int J Cardiol</i>. 2005;101(1):9-17. doi:10.1016/j.ijcard.2004.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15860377/pubmed" id="15860377" target="_blank">15860377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22480340">
<a name="22480340"></a>Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. <i>Drugs</i>. 2012;72(6):773-788. doi:10.2165/11632010-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22480340/pubmed" id="22480340" target="_blank">22480340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lentine.2022">
<a name="Lentine.2022"></a>Lentine KL, Brennan DC. Kidney transplantation in adults: Lipid abnormalities after renal transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686673">
<a name="12686673"></a>Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. <i>Nephrol Dial Transplant</i>. 2003;18(5):967-976. doi:10.1093/ndt/gfg048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12686673/pubmed" id="12686673" target="_blank">12686673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lipitor.1">
<a name="Lipitor.1"></a>Lipitor (atorvastatin) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lipitor.2">
<a name="Lipitor.2"></a>Lipitor (atorvastatin) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; Writing Committee. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18311771">
<a name="18311771"></a>Marie I, Delafenêtre H, Massy N, Thuillez C, Noblet C; Network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. <i>Arthritis Rheum</i>. 2008;59(3):367-372. doi:10.1002/art.23309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18311771/pubmed" id="18311771" target="_blank">18311771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12915827">
<a name="12915827"></a>McCrindle BW, Ose L, and Marais AD, “Efficacy and Safety of Atorvastatin in Children and Adolescents With Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial,” <i>J Pediatr</i>, 2003, 143(1):74-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12915827/pubmed" id="12915827" target="_blank">12915827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," <i>Circulation</i>, 2007, 115(14):1948-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al, “Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,” [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20155993">
<a name="20155993"></a>Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D. Atorvastatin-induced prolonged cholestasis with bile duct damage. <i>Clin Drug Investig</i>. 2010;30(3):205-209. doi:10.2165/11531660-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/20155993/pubmed" id="20155993" target="_blank">20155993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23889738">
<a name="23889738"></a>Motzkus-Feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in Veterans with cirrhosis. <i>Aliment Pharmacol Ther.</i> 2013;38(6):611-618. doi:10.1111/apt.12430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23889738/pubmed" id="23889738" target="_blank">23889738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22750917">
<a name="22750917"></a>Narayanan D, Kilpatrick ES. Atorvastatin-related thrombocytopenic purpura. <i>BMJ Case Rep</i>. 2010;2010:bcr01.2010.2614. doi:10.1136/bcr.01.2010.2614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22750917/pubmed" id="22750917" target="_blank">22750917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Heart, Lung, and Blood Institute, "Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33815984">
<a name="33815984"></a>Nemati M, Srai M, Rudrangi R. Statin-induced autoimmune myopathy. <i>Cureus</i>. 2021;13(2):e13576. doi:10.7759/cureus.13576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33815984/pubmed" id="33815984" target="_blank">33815984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16377285">
<a name="16377285"></a>Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. <i>Am J Cardiol</i>. 2006;97(1):61-67. doi:10.1016/j.amjcard.2005.07.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16377285/pubmed" id="16377285" target="_blank">16377285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30580575">
<a name="30580575"></a>Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association [published correction appears in <i>Arterioscler Thromb Vasc Biol</i>. 2019;39(5):e158]. <i>Arterioscler Thromb Vasc Biol</i>. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30580575/pubmed" id="30580575" target="_blank">30580575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33779213">
<a name="33779213"></a>Parikh NI, Gonzalez JM, Anderson CAM, et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(18):e902-e916. doi:10.1161/CIR.0000000000000961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33779213/pubmed" id="33779213" target="_blank">33779213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23183941">
<a name="23183941"></a>Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. <i>Circulation</i>. 2013;127(1):96-103. doi:10.1161/CIRCULATIONAHA.112.136101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23183941/pubmed" id="23183941" target="_blank">23183941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624871">
<a name="29624871"></a>Patel SS, Guzman LA, Lin FP, et al. Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. <i>Liver Transpl.</i> 2018;24(7):872-880. doi:10.1002/lt.25067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29624871/pubmed" id="29624871" target="_blank">29624871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33781847">
<a name="33781847"></a>Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. <i>Can J Cardiol</i>. 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33781847/pubmed" id="33781847" target="_blank">33781847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15030994">
<a name="15030994"></a>Pelli N, Setti M. Atorvastatin as a trigger of autoimmune hepatitis. <i>J Hepatol</i>. 2004;40(4):716. doi:10.1016/j.jhep.2003.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15030994/pubmed" id="15030994" target="_blank">15030994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25075655">
<a name="25075655"></a>Perdices EV, Medina-Cáliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. <i>Rev Esp Enferm Dig</i>. 2014;106(4):246-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25075655/pubmed" id="25075655" target="_blank">25075655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14642636">
<a name="14642636"></a>Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. <i>J Hepatol</i>. 2003;39(6):1095-1097. doi:10.1016/s0168-8278(03)00464-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/14642636/pubmed" id="14642636" target="_blank">14642636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9613909">
<a name="9613909"></a>Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. <i>JAMA</i>. 1998;279(20):1613-1614. doi:10.1001/jama.279.20.1613-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/9613909/pubmed" id="9613909" target="_blank">9613909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pignone.2020">
<a name="Pignone.2020"></a>Pignone M. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease?search=LDL-C%20in%20primary%20prevention&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed December 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/SR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16226165">
<a name="16226165"></a>Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16226165/pubmed" id="16226165" target="_blank">16226165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.2020.1">
<a name="Rosenson.2020.1"></a>Rosenson RS, Durrington P. Familial hypercholesterolemia in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/familial-hypercholesterolemia-in-adults-treatment?search=atorvastatin&amp;source=search_result&amp;selectedTitle=4~122&amp;usage_type=default&amp;display_rank=3#H3404475154" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.2020.2">
<a name="Rosenson.2020.2"></a>Rosenson RS, Hayward RA, Lopez-Sendon J. Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15210526">
<a name="15210526"></a>Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. <i>Arch Neurol</i>. 2004;61(6):889-892. doi:10.1001/archneur.61.6.889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/15210526/pubmed" id="15210526" target="_blank">15210526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24700436">
<a name="24700436"></a>Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. <i>Hepatology</i>. 2014;60(2):679-686. doi:10.1002/hep.27157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24700436/pubmed" id="24700436" target="_blank">24700436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826975">
<a name="19826975"></a>Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. <i>Semin Liver Dis</i>. 2009;29(4):412-422. doi:10.1055/s-0029-1240010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/19826975/pubmed" id="19826975" target="_blank">19826975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33966478">
<a name="33966478"></a>Saha A, Garg A. Severe liver injury associated with high-dose atorvastatin therapy. <i>J Investig Med High Impact Case Rep</i>. 2021;9:23247096211014050. doi:10.1177/23247096211014050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33966478/pubmed" id="33966478" target="_blank">33966478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29473763">
<a name="29473763"></a>Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. <i>Expert Rev Clin Immunol</i>. 2018;14(3):215-224. doi:10.1080/1744666X.2018.1440206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29473763/pubmed" id="29473763" target="_blank">29473763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18001622">
<a name="18001622"></a>Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. <i>Curr Atheroscler Rep</i>. 2007;9(5):389-396. doi:10.1007/s11883-007-0050-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18001622/pubmed" id="18001622" target="_blank">18001622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singh.1">
<a name="Singh.1"></a>Singh KN, Perez LKM, Singh A, Carey W. Safety of statins in decompensated cirrhosis in patients listed for liver transplantation.<i> Am J Gastroenterol.</i> 2019;114(suppl):S561–562. doi:10.14309/01.ajg.0000593396.52814.ce</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27484241">
<a name="27484241"></a>Skilving I, Eriksson M, Rane A, Ovesjö ML. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. <i>Eur J Clin Pharmacol</i>. 2016;72(10):1171-1176. doi:10.1007/s00228-016-2105-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/27484241/pubmed" id="27484241" target="_blank">27484241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11558482">
<a name="11558482"></a>Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. <i>Lancet</i>. 2001;357(9256):577-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/11558482/pubmed" id="11558482" target="_blank">11558482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14696880">
<a name="14696880"></a>Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/14696880/pubmed" id="14696880" target="_blank">14696880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29684459">
<a name="29684459"></a>Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of dyslipidemia in common liver diseases.<i> Clin Gastroenterol Hepatol.</i> 2018;16(8):1189-1196. doi:10.1016/j.cgh.2018.04.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29684459/pubmed" id="29684459" target="_blank">29684459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29424763">
<a name="29424763"></a>Spiro J, Butts M. Atorvastatin-induced dermatomyositis: resolution with change in statin? <i>J Clin Rheumatol</i>. 2018;24(7):406-409. doi:10.1097/RHU.0000000000000709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/29424763/pubmed" id="29424763" target="_blank">29424763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14636905">
<a name="14636905"></a>Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E; HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. <i>Am J Cardiol</i>. 2003;92(11):1287-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/14636905/pubmed" id="14636905" target="_blank">14636905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9549635">
<a name="9549635"></a>Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. <i>J Clin Pharmacol</i>. 1997;37(9):816-819. doi:10.1002/j.1552-4604.1997.tb05629.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/9549635/pubmed" id="9549635" target="_blank">9549635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in <i>Circulation</i>. 2014;129(25)(suppl 2):S46-S48; <i>Circulation</i>. 2015;132(25):e396]. <i>Circulation</i>. 2014;129(25)(suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25694464">
<a name="25694464"></a>Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>Eur Heart J</i>. 2015;36(17):1012-1022. doi:10.1093/eurheartj/ehv043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/25694464/pubmed" id="25694464" target="_blank">25694464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33726685">
<a name="33726685"></a>Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.<i> BMC Gastroenterol.</i> 2021;21(1):120. doi:10.1186/s12876-021-01704-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33726685/pubmed" id="33726685" target="_blank">33726685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24729773">
<a name="24729773"></a>Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. <i>Gastroenterol Hepatol (N Y)</i>. 2013;9(9):605-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24729773/pubmed" id="24729773" target="_blank">24729773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16581332">
<a name="16581332"></a>Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. <i>Am J Cardiol</i>. 2006;97(8A):69C-76C. doi:10.1016/j.amjcard.2005.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16581332/pubmed" id="16581332" target="_blank">16581332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24435290">
<a name="24435290"></a>Tuccori M, Montagnani S, Mantarro S, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. <i>CNS Drugs</i>. 2014;28(3):249-272. doi:10.1007/s40263-013-0135-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/24435290/pubmed" id="24435290" target="_blank">24435290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34044205">
<a name="34044205"></a>Vahedian-Azimi A, Makvandi S, Banach M, Reiner Ž, Sahebkar A. Fetal toxicity associated with statins: a systematic review and meta-analysis. <i>Atherosclerosis</i>. 2021a;327:59-67. doi:10.1016/j.atherosclerosis.2021.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34044205/pubmed" id="34044205" target="_blank">34044205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34601188">
<a name="34601188"></a>Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. <i>Atherosclerosis</i>. 2021b;336:1-11. doi:10.1016/j.atherosclerosis.2021.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34601188/pubmed" id="34601188" target="_blank">34601188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30944904">
<a name="30944904"></a>Villa L, Lerario A, Calloni S, et al. Immune-mediated necrotizing myopathy due to statins exposure. <i>Acta Myol</i>. 2018;37(4):257-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/30944904/pubmed" id="30944904" target="_blank">30944904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27754879">
<a name="27754879"></a>Wiggins BS, Saseen JJ, Page RL 2nd, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/27754879/pubmed" id="27754879" target="_blank">27754879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23725984">
<a name="23725984"></a>Wu du C. Hepatitis B virus reactivation associated with atorvastatin. <i>Int J Infect Dis</i>. 2013;17(11):e1069-e1070. doi:10.1016/j.ijid.2013.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23725984/pubmed" id="23725984" target="_blank">23725984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33019469">
<a name="33019469"></a>Xu Y, Wu Y. Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: a case report and literature review. <i>Medicine (Baltimore)</i>. 2020;99(40):e22572. doi:10.1097/MD.0000000000022572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/33019469/pubmed" id="33019469" target="_blank">33019469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34330325">
<a name="34330325"></a>Zereshkian A, Waserman S. Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms. <i>Allergy Asthma Clin Immunol</i>. 2021;17(1):81. doi:10.1186/s13223-021-00581-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/34330325/pubmed" id="34330325" target="_blank">34330325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31791994">
<a name="31791994"></a>Zhang W, Prince HM, Reardon K. Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab. <i>BMJ Case Rep</i>. 2019;12(11):e232406. doi:10.1136/bcr-2019-232406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/31791994/pubmed" id="31791994" target="_blank">31791994</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12908 Version 745.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
